DE60118547D1 - Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält - Google Patents

Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält

Info

Publication number
DE60118547D1
DE60118547D1 DE60118547T DE60118547T DE60118547D1 DE 60118547 D1 DE60118547 D1 DE 60118547D1 DE 60118547 T DE60118547 T DE 60118547T DE 60118547 T DE60118547 T DE 60118547T DE 60118547 D1 DE60118547 D1 DE 60118547D1
Authority
DE
Germany
Prior art keywords
thalidomide
treatment
colorectal cancer
irinotecane
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118547T
Other languages
English (en)
Other versions
DE60118547T2 (de
Inventor
Rangaswamy Govindarajan
Andrew Zeitlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Celgene Corp
Original Assignee
University of Arkansas
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas, Celgene Corp filed Critical University of Arkansas
Application granted granted Critical
Publication of DE60118547D1 publication Critical patent/DE60118547D1/de
Publication of DE60118547T2 publication Critical patent/DE60118547T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60118547T 2000-05-15 2001-05-10 Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält Expired - Lifetime DE60118547T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20414200P 2000-05-15 2000-05-15
US204142P 2000-05-15
PCT/US2001/015326 WO2001087306A2 (en) 2000-05-15 2001-05-10 Compositions and methods for the treatment of colorectal cancer

Publications (2)

Publication Number Publication Date
DE60118547D1 true DE60118547D1 (de) 2006-05-18
DE60118547T2 DE60118547T2 (de) 2007-02-01

Family

ID=22756801

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118547T Expired - Lifetime DE60118547T2 (de) 2000-05-15 2001-05-10 Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält

Country Status (13)

Country Link
US (2) US6914067B2 (de)
EP (1) EP1286671B1 (de)
JP (1) JP4679028B2 (de)
AT (1) ATE322265T1 (de)
AU (2) AU2001261473B2 (de)
CA (1) CA2408710C (de)
DE (1) DE60118547T2 (de)
DK (1) DK1286671T3 (de)
ES (1) ES2261415T3 (de)
HK (1) HK1053975A1 (de)
NZ (1) NZ522766A (de)
PT (1) PT1286671E (de)
WO (1) WO2001087306A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2005504759A (ja) * 2001-07-23 2005-02-17 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (de) 2002-10-15 2008-03-19 Celgene Corporation Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) * 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
AP2006003637A0 (en) * 2003-11-06 2006-06-30 Celgene Corp Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1746976B1 (de) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposome zur abgabe von arzneimitteln
CA2503099A1 (en) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
CN101180061A (zh) * 2005-05-19 2008-05-14 普罗米蒂克生物科学公司 化合物、含有此类化合物的组合物、和治疗转移性黑素瘤和其它癌症的方法
KR20080066663A (ko) * 2005-09-21 2008-07-16 씨씨씨 디아그노스틱스 엘엘씨 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법
US20070219825A1 (en) * 2005-11-23 2007-09-20 Maetzold Derek J Method of managing and reducing side effects associated with exposure to a drug
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HRP20230265T1 (hr) 2014-08-22 2023-04-14 Celgene Corporation Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (de) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Kombinationstherapie unter verwendung von liposomalem irinotecan und einem parp-hemmer zur behandlung von krebs
AU2016310476B8 (en) 2015-08-21 2021-10-07 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MA42991A (fr) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd Stabilisation de compositions pharmaceutiques de camptothécine
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
JP2019533684A (ja) 2016-11-02 2019-11-21 イプセン バイオファーム リミティド リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN116333154A (zh) * 2019-08-19 2023-06-27 美勒斯公司 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5955466A (en) * 1997-02-27 1999-09-21 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea

Also Published As

Publication number Publication date
US6914067B2 (en) 2005-07-05
WO2001087306A8 (en) 2002-10-03
DK1286671T3 (da) 2006-07-17
US20020035091A1 (en) 2002-03-21
EP1286671A2 (de) 2003-03-05
PT1286671E (pt) 2006-08-31
JP4679028B2 (ja) 2011-04-27
EP1286671B1 (de) 2006-04-05
JP2003533483A (ja) 2003-11-11
DE60118547T2 (de) 2007-02-01
AU2001261473B2 (en) 2006-09-14
CA2408710A1 (en) 2001-11-22
US20050203060A1 (en) 2005-09-15
US7479499B2 (en) 2009-01-20
HK1053975A1 (en) 2003-11-14
WO2001087306A2 (en) 2001-11-22
ATE322265T1 (de) 2006-04-15
NZ522766A (en) 2005-09-30
ES2261415T3 (es) 2006-11-16
CA2408710C (en) 2010-01-26
AU6147301A (en) 2001-11-26

Similar Documents

Publication Publication Date Title
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
MXPA02011218A (es) Composiciones y metodos para el tratamiento de cancer.
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
DE602006021348D1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
ATE359072T1 (de) Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition